Though relapsing-remitting multiple sclerosis, or RRMS, can be managed with many of the approved treatments for MS symptoms, there is still no scientifically proven, FDA-cleared way to predict when or ...

Siemens Healthineers has inked what it describes as a “master collaboration agreement” with Novartis to help provide diagnostic tests linked to therapies across the drugmaker’s pipeline. To start, the ...

Multiple sclerosis (MS) is one of the most common autoimmune diseases affecting the brain and spinal cord, with 2.9 million ...

A wearable system that measures the brain's electrical activity can show how brain circuits are affected in people with MS, a ...

LONDON — Previous research has shown that providing a clinically definite multiple sclerosis (MS) diagnosis often takes several weeks or even months. But new research suggests that a new "technology ...

MYND Diagnostics will be initiating a clinical validation study on the use of its proprietary biomarker testing in Multiple Sclerosis diagnostics "According to the National Multiple Sclerosis Society, ...

A previously "hidden" subtype of Multiple Sclerosis (MS)—a condition that affects the brain and spinal cord—has been uncovered. The distinct subtype exhibits "significant cognitive deficits with ...

MOG-IgG positivity is rare in MS patients, complicating diagnosis and treatment, especially in Asian populations with lower ...

Share on Pinterest Scientists are trying to find blood biomarkers that may help predict the course of disease in MS. Betsie Van der Meer/Getty Images As of 2020, about 2.8 million people globally have ...

Olfactory dysfunction in MS may be linked to nasal microbial changes, not just central inflammation. MS patients showed lower olfactory test scores and distinct nasal microbiome differences compared ...

Roche's experimental multiple sclerosis drug achieved its main goal in one of two key late-stage trials testing it against ...